Compare · ENZ vs LH
ENZ vs LH
Side-by-side comparison of Enzo Biochem Inc. (ENZ) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENZ and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH carries a market cap of $29.86B.
- LH has hit the wire 10 times in the past 4 weeks while ENZ has been quiet.
- LH has more recent analyst coverage (25 ratings vs 0 for ENZ).
- Company
- Enzo Biochem Inc.
- Labcorp Holdings Inc.
- Price
- $0.32-15.01%
- $359.97-0.51%
- Market cap
- -
- $29.86B
- 1M return
- -
- +17.00%
- 1Y return
- -
- +39.93%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- 1988
- News (4w)
- 0
- 10
- Recent ratings
- 0
- 25
Enzo Biochem Inc.
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ÂSTAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest ENZ
- Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
- Enzo Biochem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction
- Enzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 25 filed by Enzo Biochem Inc.
- Enzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
- Enzo Biochem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
- SEC Form 10-Q filed by Enzo Biochem Inc.
Latest LH
- SEC Form 10-Q filed by Labcorp Holdings Inc.
- SEC Form 8-K filed by Labcorp Holdings Inc.
- Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
- Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
- Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
- SEC Form 8-K filed by Labcorp Holdings Inc.
- Labcorp Declares Quarterly Dividend
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
- Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
- Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test